New trial available: Click on any alert below and access our regulatory alerts and get timely notifications sent to your inbox for 7 days.
10th November 2022
US - Colorado: Proposition 122, a ballot measure to decriminalise the possession and use and allow for regulated distribution of certain psychedelic substances, appears poised to pass as votes continue to be counted, press reports. The measure would allow for the adult (21+) possession and use of natural psychedelics, such as psilocybin, dimethyltryptamine (DMT), and ibogaine, and allow for their distribution in licensed healing centres, where participants can purchase and consume the substances under supervision. Oregon voters passed a similar measure in 2020 that allows adults access to psilocybin mushrooms.
3rd June 2022
23rd May 2022
US - Colorado: Senate Bill 22-205 has been passed by the House and now heads to the governor for final approval. The bill originally would have cracked down on intoxicating hemp-derived products by setting THC caps. However, the amended and passed version would form a task force to study intoxicating hemp products and make legislative recommendations, and would allow the Department of Public Health and Environment to prohibit such products.
12th May 2022
9th May 2022
4th May 2022
US - Colorado: Senate Bill 22-205 has been amended, reportedly in response to a backlash from the hemp industry. The original bill would have cracked down on intoxicating hemp-derived products by setting THC caps and effectively requiring manufacturers to have a cannabis licence. The amendments would form a task force to study intoxicating hemp products and make legislative recommendations, and would allow the Department of Public Health and Environment to regulate such products. SB 22-205 has not yet been passed by either chamber.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.